Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Iberdomide Clear all
Not yet recruiting Phase 3 Interventional

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05169515
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
SC Mosunetuzumab, IV Glofitamab, Iberdomide, Golcadomide, Obinutuzumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

NCT06232044
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Iberdomide, Belantamab Mafodotin, Dexamethasone, Echocardiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
43
States / cities
Ames, Iowa • Boone, Iowa • Fort Dodge, Iowa + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

NCT02034773
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-220, Placebo
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 1, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

NCT05899738
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Iberdomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 1, 2026, 2:18 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

NCT05392946
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab, Dexamethasone, Iberdomide
Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

NCT02820935
View directory record Official record
Conditions
Pharmacokinetics
Interventions
CC-220, Rifampin, Itraconazole
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Sep 1, 2026, 2:18 PM EDT
Suspended Phase 1Phase 2 Interventional

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

NCT05199311
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Iberdomide, Oral Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Radiolabeled Study of CC-220 in Healthy Male Subjects

NCT03294603
View directory record Official record
Conditions
Healthy Volunteer
Interventions
CC-220, [14C]
Drug · Radiation
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Sep 1, 2026, 2:18 PM EDT
Not yet recruiting Early Phase 1 Interventional

Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

NCT07727668
View directory record Official record
Conditions
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Interventions
Iberdomide, CAR-T Leukapheresis, CAR-T Infusion
Drug · Procedure
Lead sponsor
Shambavi Richard
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Iberdomide, Lenalidomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
44
States / cities
Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Recruiting Phase 2 Interventional

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

NCT04776395
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

NCT04884035
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
CC-220, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, CC-99282, Polatuzumab vedotin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

NCT03135509
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-220
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 1, 2026, 2:18 PM EDT
Terminated Phase 1 Interventional

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

NCT04464798
View directory record Official record
Conditions
Lymphoma
Interventions
CC-220, Rituximab, Obinutuzumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Lake Mary, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 1, 2026, 2:18 PM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Daratumumab, Bortezomib, Iberdomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
43
States / cities
Hot Springs, Arkansas • Cerritos, California • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

NCT03824678
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
CC-220
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 1, 2026, 2:18 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

NCT07601100
View directory record Official record
Conditions
Newly Diagnosed Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib, Dexamethesone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

NCT05434689
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Iberdomide, Daratumumab, Dexamethasone, Carfilzomib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Birmingham, Alabama • Columbus, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Recruiting Phase 1 Interventional

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

NCT06465316
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Iberdomide, Magnetic Resonance Imaging, Positron Emission Tomography, Teclistamab
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Derby, Connecticut • Guilford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Recruiting Phase 2 Interventional

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

NCT06107738
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Iberdomide, Daratumumab/rHuPH20 Co-formulation
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Detroit, Michigan • Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

NCT03310619
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions
JCAR017, Durvalumab, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 1, 2026, 2:18 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

NCT06892522
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Carfilzomib, Mezigdomide, Iberdomide, ABBV-2001
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
14
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 1, 2026, 2:18 PM EDT
Recruiting Phase 1 Interventional

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

NCT06348108
View directory record Official record
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions
Talquetamab, Iberdomide, Dexamethasone, Bone Marrow Biopsy
Biological · Drug · Procedure
Lead sponsor
Alfred Chung, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 1, 2026, 2:18 PM EDT